COMMUNIQUÉS West-GlobeNewswire
-
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
15/07/2026 -
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026 -
Attovia Therapeutics Appoints John W. Smither to Board of Directors
15/07/2026 -
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
15/07/2026 -
Biogen Appoints Michael J. Parini as Chief Legal Officer
15/07/2026 -
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
15/07/2026 -
VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
15/07/2026 -
SBC Medical to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:30 a.m. ET
15/07/2026 -
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
15/07/2026 -
Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury
15/07/2026 -
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
15/07/2026 -
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
15/07/2026 -
Alembic Therapeutics LLC Announces Exclusive U.S. Distribution of NUVESSA® (metronidazole vaginal gel 1.3%)
15/07/2026 -
Mixie Technologies, Inc. (OTC: MIXE) Completes Corporate Rebranding and Trading Symbol Change
15/07/2026 -
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
15/07/2026 -
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
15/07/2026 -
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
15/07/2026 -
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
15/07/2026 -
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
15/07/2026
Pages